ArticleClinical kidney journal2022
Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care.
Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors.Renal failure · 2026Observational
- Global trends and projections of early-onset CKD burden: a GBD 2021 analysis.Clinical kidney journal · 2026Article
- Pharmacologic management of renal involvement in monogenic autoinflammatory diseases.European journal of medical research · 2026Review
- Factors associated with awareness of chronic kidney disease, and impact of awareness on renal prognosis.Clinical and experimental nephrology · 2025Article
- Critical Review of the Benefit from Early Pharmacological and Dietary Support for Patients with Moderate-to-Severe (Non-Terminal) Chronic Kidney Disease.Biomedicines · 2025Review
- Global, regional, and national trends in chronic kidney disease burden (1990-2021): a systematic analysis of the global burden of disease in 2021.Tropical medicine and health · 2025Article
- Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021.BMC public health · 2025Article
- Nomenclature of renal involvement in diabetes mellitus: unify to manage diversity.Frontiers in medicine · 2025Review
- High unawareness of kidney dysfunction in European older adults and the importance of early detection through comorbidities.PloS one · 2025Article
- Assessment of Potentially Nephrotoxic Drug Prescriptions in Chronic Kidney Disease Outpatients at a Hospital in Indonesia.International journal of nephrology and renovascular disease · 2025Article
- Fabrication of Nanobioengineered Interfaces Utilizing Quaternary Nanocomposite for Highly Efficient and Selective Electrochemical Biosensing of Urea.Langmuir : the ACS journal of surfaces and colloids · 2024Article
- Novel Insights into Diabetic Kidney Disease.International journal of molecular sciences · 2024Review
- The impact of population ageing on the burden of chronic kidney disease.Nature reviews. Nephrology · 2024Review
- Chronic kidney disease and the global public health agenda: an international consensus.Nature reviews. Nephrology · 2024Review
- Drug stewardship in chronic kidney disease to achieve effective and safe medication use.Nature reviews. Nephrology · 2024Review
- Projecting the economic burden of chronic kidney disease at the patient level (EClinicalMedicine · 2024Article
- Medication patterns and dosing guidance in pediatric patients supported with intermittent hemodialysis or continuous kidney replacement therapy.Pediatric nephrology (Berlin, Germany) · 2024Review
- Nephrotoxic drug burden and predictors of exposure among patients with renal impairment in Ethiopia: A multi-center study.Heliyon · 2024Article
- Differences in the epidemiology, management and outcomes of kidney disease in men and women.Nature reviews. Nephrology · 2024Review
- Best-Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Background: To characterize the use of nephrotoxic medications in patients with chronic kidney disease (CKD) Stages G3-5 in routine care. Methods: We studied cohorts of adults with confirmed CKD G3-5 undergoing routine care from 1 January 2016 through 31 December 2018 in two health systems [Stockholm CREAtinine Measurements (SCREAM), Stockholm, Sweden ( Results: During a 1-year period, 20% (SCREAM) and 17% (Geisinger) of patients with CKD received at least one nephrotoxic medication. Among the top nephrotoxic medications identified in both cohorts were non-steroidal anti-inflammatory drugs (given to 11% and 9% of patients in SCREAM and Geisinger, respectively), antivirals (2.5% and 2.0%) and immunosuppressants (2.7% and 1.5%). Bisphosphonate use was common in SCREAM (3.3%) and fenofibrates in Geisinger (3.6%). Patients <65 years of age, women and those with CKD G3 were at higher risk of receiving nephrotoxic medications in both cohorts. Notably, provider awareness of a patient's CKD was associated with lower odds of nephrotoxic medication use {odds ratios [OR] 0.85[95% confidence interval (CI) 0.80-0.90] in SCREAM and OR 0.80 [95% CI 0.72-0.89] in Geisinger}. Conclusions: One in five patients with CKD received nephrotoxic medications in two distinct health systems. Strategies to increase physician's awareness of patients' CKD and knowledge of drug nephrotoxicity may reduce prescribing nephrotoxic medications and prevent iatrogenic kidney injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.